May 16th 2024
Data from a meta-analysis of evinacumab trials reveal significant reductions in cholesterol and other lipid markers among patients with dyslipidemia.
Statin Use Associated with Increased Odds of Worsening Diabetes, Study Finds
October 5th 2021Using data from more than 80k matched pairs of statin users and comparators, investigators from UT Southwestern Medical Center found initiation of statin therapy was associated with an increased likelihood of diabetes progression, including risk of hyperglycemia and ketoacidosis.
Return to Healthy Weight Could Reverse Cardiovascular Risk in Obesity
September 30th 2021An analysis of NHANES data presented at EASD 2021 suggests a return to a healthy weight in patients with obesity could result in reverse some of the cardiovascular risk associated with obesity, including high blood pressure and cholesterol disorders.
Evolocumab Approved for Pediatric Patients with Heterozygous Familial Hypercholesterolemia
September 27th 2021Announced on September 24, the approval is for use as an adjunct to diet and other LDL-C-lowering therapies for reducing LDL-C in patients aged 10 years and older with heterozygous familial hypercholesterolemia.
Ticagrelor Monotherapy Reduces Bleeding Events vs DAPT with Aspirin in HBR Patients
August 30th 2021TWILIGHT-HBR suggests ticagrelor monotherapy could lower bleeding risk among patients meeting ARC-HBR criteria. Study presenter Davide Cao, MD, offers further perspective on results of the post hoc analysis.
TWILIGHT Analysis Suggests Ticagrelor Monotherapy Preferable in Concomitant Diabetes and CKD
August 30th 2021A post hoc analysis of the TWILIGHT trial suggests the effects of ticagrelor monotherapy observed in the overall trial were consistent, irrespective of diabetes and chronic kidney disease status.
Deepak Bhatt, MD: Icosapent Ethyl Reduces Event Risk in Patients with Prior Myocardial Infarction
August 28th 2021An ESC Congress 2021 analysis suggests icosapent ethyl was associated with a 35% reduction in total primary end point events among patients with a history of myocardial infarction prior to enrollment in the REDUCE-IT trial.
MASTER DAPT: One-Month of DAPT Benefits Patients with High Bleeding Risk Following Stenting
August 28th 2021Results of MASTER DAPT demonstrate an abbreviated period of DAPT rather than a standard approach preserves ischemic benefits and reduces bleeding risk in patients at a high bleeding risk following stent implantation.
In High-Risk Patients, Most DOACs Reduce Stroke Risk Without Increasing Bleeding Risk vs Warfarin
August 16th 2021Using propensity score-matching, a new study is providing insight into the risk reduction and bleeding risk associated with various DOACs versus warfarin and one another in patients with nonvalvular atrial fibrillation and an increased gastrointestinal bleeding risk.
GOULD Registry Details Subpar Levels of Intensifying Lipid-Lowering Therapies in ASCVD Patients
June 17th 2021Analysis of 2-year data from the GOULD Registry indicates new strategies are needed to address the suboptimal levels of lipid-lowering therapy intensification among patients with ASCVD and increased LDL-C.
Dissonance Between Clinicians and Patients Could Prevent Optimal Prescription of Oral Anticoagulants
May 19th 2021An analysis of patient and clinician responses to surveys within BOAT-AF suggests many were willing to consider DOACs but were never prescribed anticoagulation and also provides insight into how trends in this cohort compared to those in the ACC's PINNACLE registry.
ACC.21 Simulation Study Estimates CV Event Risk Reduction with Bempedoic Acid
May 19th 2021A pooled risk simulation of phase 3 data of bempedoic acid suggests the first-in-class ATP citrate lyase inhibitor could reduce risk of cardiovascular events in patients with established cardiovascular disease and elevated LDL-C.
How STRENGTH Results Impact REDUCE-IT, with Deepak Bhatt, MD, MPH
May 16th 2021As part of our coverage of ACC.21, Practical Cardiology reached out to Deepak Bhatt, MD, MPH, to learn about his reaction to the latest analysis of the STRENGTH trial and how it might impact how REDUCE-IT results are interpreted.
ADAPTABLE Study Finds Optimal Aspirin Dose Could Come Down to Patient Preference
May 15th 2021The ADAPTABLE study from DCRI suggests patients with existing CVD saw similar outcomes whether they were receiving 81 mg or 325 mg aspirin, but also suggests patients with the higher dose were more likely to discontinue therapy.
Time of Appointment Could Influence Prescribing Practices for Statin Therapy
May 11th 2021The latest study from Penn Medicine's Nudge Unit is detailing the impact of time of appointment on the probability of receiving a prescription for statin therapy at primary care clinics among patients with an indication for statin therapy.
AHA/ASA Release Guidance for Treatment of COVID-19 Vaccine-Related Clotting, Low Platelet Counts
May 3rd 2021The American Heart Association and American Stroke Association have released a special report related to the treatment of blood clots or low platelet counts related to the COVID-19 vaccine, which has garnered mass amounts of attention despite being a rare complication.
Extended-Duration DAPT Reduces Mortality, Event Rate in TWILIGHT-like Patients
April 29th 2021An SCAI 2021 analysis of more than 4k patients with characteristics similar to those included in the TWILIGHT trial indicates extended-duration DAPT, defined as a duration of more than 12 months post-PCI, was a more efficacious approach than short-term DAPT in this patient population.